Hunan Jingfeng Pharmaceutical Co

Hunan Jingfeng Pharmaceutical Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Hunan Jingfeng Pharmaceutical Co (000908.SZ) as of Oct 21, 2026 is -16.28. In the previous year, Net Debt to Free Cash Flow Ratio was 23.56 — a change of -169.09% (lower).

Net Debt/FCF

-16.28

YoY

-169.09%

Last updated:

Net Debt to Free Cash Flow Ratio of Hunan Jingfeng Pharmaceutical Co is 2024 -16.28 . Net Debt to Free Cash Flow Ratio of Hunan Jingfeng Pharmaceutical Co was 2023 23.56 . It decreases by -169.09% lower compared to the previous year.

The Hunan Jingfeng Pharmaceutical Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
-8.79 CNY
Jan 1, 2018
6.99 CNY
Jan 1, 2019
-16.65 CNY
Jan 1, 2020
-3.42 CNY
Jan 1, 2021
8.18 CNY
Jan 1, 2022
3.80 CNY
Jan 1, 2023
23.56 CNY
Jan 1, 2024
-16.28 CNY
The Hunan Jingfeng Pharmaceutical Co Net Debt/FCF history
YEARNet Debt/FCFYoY
-16.28-169.09%
23.56+519.56%
3.80-53.52%
8.18-339.00%
-3.42-79.44%
-16.65-338.13%
6.99-179.58%
-8.79+171.84%
-3.23+168.48%
-1.20-139.45%
3.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hunan Jingfeng Pharmaceutical Co Stock analysis

What does Hunan Jingfeng Pharmaceutical Co do? Hunan Jingfeng Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical and biological drugs. Its main product categories include cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs, and anti-infective drugs. The company distributes these products domestically and also engages in commodity import and export trading, business management and consulting, and medical technology consulting services. Sales are primarily directed at the domestic market with no mention of international distribution channels. The firm's revenue streams are derived from pharmaceutical sales, particularly in cardiovascular, oncology, and infectious disease treatments, alongside ancillary services such as medical technology consulting. The domestic market remains the sole focus for product distribution, with no indication of export-oriented sales. The company's operations are centered on drug manufacturing and related consulting services, targeting healthcare providers and domestic consumers through established distribution networks. Hunan Jingfeng Pharmaceutical's business model emphasizes product diversity across multiple therapeutic areas, including cardiovascular, oncology, and infectious diseases. The company's revenue is driven by both direct pharmaceutical sales and ancillary consulting services, with all activities confined to the domestic market. The absence of international operations or export-focused strategies is consistent with the business description provided. Hunan Jingfeng Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hunan Jingfeng Pharmaceutical Co stock

Net Debt to Free Cash Flow Ratio of Hunan Jingfeng Pharmaceutical Co is -16.28 in 2024.

Net Debt to Free Cash Flow Ratio of Hunan Jingfeng Pharmaceutical Co changed from 23.56 to -16.28, representing a -169.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Hunan Jingfeng Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Hunan Jingfeng Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Hunan Jingfeng Pharmaceutical Co

All Key Metrics — Hunan Jingfeng Pharmaceutical Co